- Home
- LVLU vs KZR Comparison
LVLU vs KZR Comparison
Compare LVLU & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- KZR
- Stock Information
- Founded
- LVLU 1996
- KZR 2015
- Country
- LVLU United States
- KZR United States
- Employees
- LVLU N/A
- KZR N/A
- Industry
- LVLU Catalog/Specialty Distribution
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- KZR Health Care
- Exchange
- LVLU Nasdaq
- KZR Nasdaq
- Market Cap
- LVLU 36.0M
- KZR 43.0M
- IPO Year
- LVLU 2021
- KZR 2018
- Fundamental
- Price
- LVLU $0.83
- KZR $6.05
- Analyst Decision
- LVLU Hold
- KZR Hold
- Analyst Count
- LVLU 3
- KZR 2
- Target Price
- LVLU $1.58
- KZR $9.00
- AVG Volume (30 Days)
- LVLU 23.5K
- KZR 26.2K
- Earning Date
- LVLU 03-05-2025
- KZR 03-13-2025
- Dividend Yield
- LVLU N/A
- KZR N/A
- EPS Growth
- LVLU N/A
- KZR N/A
- EPS
- LVLU N/A
- KZR N/A
- Revenue
- LVLU $324,699,000.00
- KZR N/A
- Revenue This Year
- LVLU N/A
- KZR N/A
- Revenue Next Year
- LVLU $1.72
- KZR N/A
- P/E Ratio
- LVLU N/A
- KZR N/A
- Revenue Growth
- LVLU N/A
- KZR N/A
- 52 Week Low
- LVLU $0.75
- KZR $5.20
- 52 Week High
- LVLU $2.13
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- LVLU 38.00
- KZR 43.79
- Support Level
- LVLU $0.81
- KZR $5.86
- Resistance Level
- LVLU $0.85
- KZR $6.57
- Average True Range (ATR)
- LVLU 0.07
- KZR 0.27
- MACD
- LVLU 0.01
- KZR 0.02
- Stochastic Oscillator
- LVLU 34.43
- KZR 25.97
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.